Panagora Asset Management’s Carisma Therapeutics CARM Stock Holding History

Panagora Asset Management’s Portfolio CARM Stock Details CARM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-313	Closed	-$4K	–	2572
2020 Q1	$4K	Buy	+313	New	+$5.13K	﹤0.01%	2287
2018 Q3	–	Sell	-462	Closed	-$18K	–	2413
2018 Q2	$18K	Buy	+462	New	+$20.4K	﹤0.01%	2200
2018 Q1	–	Sell	-174	Closed	-$3K	–	2348
2017 Q4	$3K	Sell	174 -826	-83%	-$15.4K	﹤0.01%	2268
2017 Q3	$32K	Sell	1,000 -214	-18%	-$5.98K	﹤0.01%	2122
2017 Q2	$38K	Hold	1,214	–	–	﹤0.01%	2128
2017 Q1	$53K	Buy	+1,214	New	+$50.6K	﹤0.01%	2005

Other funds holding CARM

TRV GP Boston, Massachusetts $18.9M AUM 541.67% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

SWP

Stratos Wealth Partners Beachwood, Ohio $9.93B AUM 28.91% 1-Year Est. Return

Panagora Asset Management's CARM Position: Q2 2020 in Review

Panagora Asset Management sold out of Carisma Therapeutics (CARM) in Q2 2020, closing a stake of 313 shares — an estimated $4K sold.

Panagora Asset Management first reported a position in CARM in Q1 2017 and held it in 6 quarters. The position peaked at $53K in Q1 2017. 40 funds tracked by Wall St. Rank hold CARM as of Q2 2020.

Panagora Asset Management reported no remaining Carisma Therapeutics position as of Q2 2020 after selling out during the quarter.
Panagora Asset Management sold 313 Carisma Therapeutics shares in Q2 2020, an estimated $4K.
Panagora Asset Management first reported a position in Carisma Therapeutics in Q1 2017 and held it in 6 quarters.
Panagora Asset Management's Carisma Therapeutics position peaked at $53K in Q1 2017.
40 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q2 2020.

Based on Panagora Asset Management's 13F filing for Q2 2020, filed 12 Aug 2020.